Wednesday, May 25, 2016 1:26:06 PM
The technical picture, as was pointed out by an earlier post.
If, as EMH says, prices respond instantly to news, then technical analysis would not work. And though markets do get it right after a while, the response is not instantaneous. Various cognitive biases, such as the conservatism bias, and the confirmation bias prevent people from adjusting their expectations to news as rapidly as they should. Human information processing limits and crowd dynamics, like herding and information cascades also operate to slow the diffusion of new information through out the market.
Is is the retarded diffusion of information that allows price trends to develop and this in turn allows technical analysis to work.
But yes, if there is a major news announcement such as
NNVC makes a public announcement the ability to produce 500 g batches of the micelle that meet specifications. They have not moved beyond 200g for over a year and a half (see latest 10-Q SEC filing).
OR
NNVC puts out a PR release that all the drug candidate material for either FluCide or HerpeCode needed for final toxicology testing has been sent off for testing. (FluCide tox testing has been delayed because a lack of production capacity. HerpeCide drug program is still on hold because the animal lab studies to have not yet determined which ligand will be best. HerpeCide selection was to be done by August I think. But as will all their prior expectations about compleation dates they will probably take longer.
OR
Something even better.
In the absence of such material events, the stock will drift lower as investors come slowly and grudgingly to the realization that they've been had by an unscrupulous stock promoter.
Hope this is helpful to some.
Trendliner
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM